ALEPH-FARMS
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced that it has been officially recognized by the Agriculture Innovation Mission for Climate (AIM for Climate) as an Innovation Sprint Partner. As part of this innovation sprint, $40 million is being invested in cellular agriculture R&D over the next five years through Aleph Farms with the support of L Catterton, Strauss Group, VisVires New Protein, CPT Capital, Synthesis Capital, Food Tank and Christensen Global. Aleph Farms will introduce its products into global markets as soon as regulatory processes conclude and approvals are finalized.
The United States and the United Arab Emirates, alongside 39 other countries and over 180 non-governmental partners, officially launched the AIM for Climate initiative at the 26th United Nations Climate Change Conference of Parties (also known as COP26) in Glasgow, Scotland in 2021. The initiative galvanizes support and investments for innovation geared towards climate-smart agriculture and food systems, enabling solutions where global hunger and the climate crisis intersect. Of AIM for Climate’s four focal areas for innovation sprints in 2022, cellular agriculture addresses two in particular: methane reduction and emerging technologies in agriculture.
When supplementing sustainable segments of conventional animal agriculture, cellular agriculture can rapidly reduce emissions of methane, a powerful (yet short-lived) greenhouse gas of which livestock is a main source. Compared to conventional beef production, cultivated meat that is produced via cellular agriculture can reduce greenhouse gas emissions by 92% and water use by 78%, according to an independent Life Cycle Analysis conducted by CE Delft. Cultivated meat is also far more efficient than cows at converting feed into meat. By requiring 95% less land, cultivated meat opens up new opportunities for land use, including producing more food and re-wilding habitats for biodiversity, the latter of which further reduces emissions. In addition, because cultivated meat is produced in closed systems, its production is feasible in locations where extreme climate and resource scarcity prevent conventional beef production from taking place.
“Enhancing food security via cellular agriculture empowers communities and fosters regional cooperation, spurring economic growth in the process. This is why we are especially proud to be allocating these R&D funds as an AIM for Climate Innovation Sprint Partner,” said Didier Toubia, co-founder and CEO of Aleph Farms. “With cellular agriculture, humanity is better equipped to overcome significant food-related challenges and bring agricultural systems back into balance.”
Because meat represents only one-third of a cow slaughtered for conventional beef, Aleph Farms intends to continue expanding its product line to replace the whole cow. The company, the first to have grown steaks directly from non-genetically engineered animal cells, has also developed slaughter-free collagen, which has numerous applications across an array of multi-billion dollar industries.
About Aleph Farms
Aleph Farms grows cultivated beef steaks from cells that are isolated from a living cow and not immortalized or genetically modified, avoiding slaughter and achieving reduced environmental impact. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub by Strauss Group, and Professor Shulamit Levenberg of the Technion - Israel Institute of Technology. Its vision is to ensure unconditional nutrition for anyone, anytime, anywhere.
For its contributions to sustainability, Aleph Farms has received top accolades from the World Economic Forum, UNESCO, Netexplo Forum and EIT Food. The company is also part of the Private Sector Mechanism (PSM) at the UN Committee on World Food Security (CFS).
For more information, follow Aleph Farms on Instagram, Twitter, Facebook or LinkedIn or visit www.aleph-farms.com. Access the Aleph Farms press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220830005072/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 01:00:00 CET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 22:30:00 CET | Press release
New agreement for uninterrupted UHF connectivity for Australian Defence Force through 2033, With Options Extending to 2041 Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the corne
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 22:05:00 CET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 20:00:00 CET | Press release
Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain an
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 19:32:00 CET | Press release
First Marketing Authorization granted in France for the treatment of ricin poisoning, one of the most toxic natural substances in the world and a recognized priority biological threat. Ricimed® addresses a previously unmet medical need in the management of severe and potentially fatal ricin intoxications.Supported by the French Ministry of the Armed Forces and Veterans Affairs (the Directorate General of Armaments and the French Military Health Service), the development of Ricimed® illustrates Fabentech’s transition to a new scale and, with recent support from the European HERA Invest program, reinforces its positioning as a reference player in medical countermeasures against biological threats, serving both civilian and military markets. Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release featur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom